334P - Clinical significance and the detection of circulating tumor cells in peripheral blood of patients with breast cancer

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Breast Cancer, Locally Advanced
Translational Research
Presenter Jian Liu
Citation Annals of Oncology (2014) 25 (suppl_4): iv110-iv115. 10.1093/annonc/mdu328
Authors J. Liu1, Q. Zheng2, W. Huang1, F. Gong2, F. Wu1, N. Li1, K. Chen1, Y. Song3, K. Chen3, L. Zhang3, M. Ying4
  • 1Department Of Breast Medical Oncology, Fujian Provincial Cancer Hospital Affiliated to Fujian Medical University, 350014 - Fuzhou/CN
  • 2Oncological Surgery Research Unit, Fujian Provincial Cancer Hospital Affiliated to Fujian Medical University, 350014 - Fuzhou/CN
  • 3Graduate School, Fujian University of Traditional Chinese Medicine, 350122 - Fuzhou/CN
  • 4Oncological Surgery Research Unit, Fujian Provincial Cancer Hospital Affiliated to Fujian Medical University, Fuzhou, 350014 - Fuzhou/CN

Abstract

Aim

To explore the detection methods of detecting circulating tumor cells (CTCs) in peripheral blood of breast cancer patients using multiparameter flow cytometry (FCM) and analyze its clinical significance.

Methods

The breast cancer cell line SKBR-3 was serially diluted and added into the peripheral blood mononuclear cells from healthy donors to evaluate the sensitivity of FCM. Mononuclear cells were isolated from 7.5 mL peripheral venous blood of 62 patients with breast cancer and 20 cases of healthy volunteers using density gradient centrifugation. Superspeed flow cytometry were used to detect expression level of immunofluorescence antibody (EpCAM、CK18 and CD45). The amount of CTCs ≥ 5/7.5 ml in peripheral blood was considered micrometastases positive.

Results

The expression of CTCs in 20 healthy volunteers was all negative, while the positive rate was 53.2% in 62 case breast cancer patients, the difference was significant (P < 0.05); The expression of CTCs in 6 patients with III stage neoadjuvant chemotherapy and 27 patients with IV stage palliative chemotherapy before chemotherapy and 2 weeks after the second cycle of chemotherapy was detected and found the positive rate of CTCs were 72.7%(24/33) and 30.3%(10/33), the difference was statistically significant (P<0.05); the positive rate of CTCs in 62 patients with breast cancer was significantly different in different TNM staging, the expression of Ki-67, human epidermal receptor-2 (HER-2) (P<0.05), but no differences in menstrual status, the expression of ER and PR (P>0.05). The positive rate of CTCs gradually increased with positive rate of TNM staging ranks. The positive rate of CTCs was significant different among different breast cancer molecular subtypes (P < 0.05) and obviously higher in HER-2 amplification type and triple-negative type than patients with Luminal A subtype and Luminal B subtype.

Conclusions

The sensitivity and specificity of the detection of CTCs using ultra high speed flow cytometry was high. The positive rate CTCs in breast cancer patients was related to its clinical TNM staging, the expression of Ki 67 and HER-2, but unrelated to menopausal status, the expression of ER and PR. Breast cancer molecular subtypes can assess the risk of peripheral blood micrometastases, the positive rate of CTCs was high in HER-2 amplification type and triple-negative type.

Disclosure

All authors have declared no conflicts of interest.